Lilly targets RNA medicines

ELI LILLY & CO., $276.44, is a buy. The company (New York symbol LLY; TSINetwork Rating: Above Average) (www.lilly.com; Shares o/s: 952.3 million; Market cap: $262.3 billion; Dividend yield: 1.4%) has announced that it’s building a new RNA medicine centre in Boston for $700 million. Eli Lilly’s investment in… Read More

Q: Hi, Pat. What do you think of Moderna as a stock to buy, especially in light of the new Omicron variant of COVID-19? Thanks.

A: Moderna Inc., $272.83, symbol MRNA on Nasdaq (Shares outstanding: 405.4 million; Market cap: $107.6 billion; www.modernatx.com), develops messenger RNA (ribonucleic acid) vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.

However, the Cambridge, Massachusetts-based company is best known for its… Read More

Q: I am a long-time member, with most of my portfolio in stocks that you recommend. I would like your opinion of Sanofi, SNY on Nasdaq. Kind regards.

A: Sanofi (ADR), $52.11, symbol SNY on New York (ADRs outstanding: 2.5 billion; Market cap: $128.5 billion; www.sanofi.com) is a global pharmaceutical company. It offers a wide range of medicines, vaccines, and therapeutic solutions.

Its sales break down as follows: pharmaceuticals, 71%; vaccines, 17%; and consumer… Read More

Let our stock updates help direct you

DANAHER CORP. $325 is a buy. The company (New York symbol DHR; Manufacturing sector; Shares outstanding: 713.9 million; Market cap: $232.0 billion; Dividend yield: 0.3%; Takeover Target Rating: Medium; www.danaher.com) is a leading maker of precision-testing equipment and tools. Its customers include medical research labs… Read More